Korean bio stocks struggle as series of scandals weigh down the category

Kang Bong-jin and Minu Kim 2022. 1. 17. 15:36
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

South Korean bio stocks have started the new year on a bearish note, weighed down by confidence issue in the category following the embezzlement scandal at Osstem Implant, whose stock is suspended on possible delisting review, and other disgrace at bio companies.

Bellwethers Samsung Biologics and Celltrion tanked by 3 to 5 percent Monday.

MedPacto remained in the negative territory, failing to recover from a nosedive of 28 percent last Thursday due to a setback in its pivotal oncology clinical trial last week.

Daewoong Pharmaceutical lost most of its earlier gains boosted by a success in a Phase 3 trial of a new diabetes drug last week.

The bearish trend in the sector is attributable to continuous adverse events that occurred during the first two weeks of this month amid the accelerated tightening of monetary policy around the world working unfavorably for growth stocks.

Lack of big license or M&A news from Korean names at this year¡¯s JP Morgan Healthcare Conference, the largest pharma trade show, was also a disappointment.

The conference was held online, and the overall vibe cooled with no major M&A news, said Heo Hye-min, a Kiwoom Securities researcher, adding license transactions during this year's JP Morgan Conference fell compared to last year due to slow M&A activity.

The outlook is grim as financial authorities may impose sanctions on Celltrion for accounting fraud.

In the worst-case scenario, Celltrion stocks could be suspended from trading violations at Celltrion and Celltrion Healthcare amount to 98.5 billion won ($82.6 million) and 50.8 billion won, respectively.

Osstem Implant stocks were suspended from trading due to a charge of 221.5 won embezzlement, which is 108 percent of the company¡¯s equity capital, on Jan. 3. The company will receive a listing eligibility review on Jan. 24.

The accounting scandal of Samsung Biologics took five months for the financial authorities to come to a conclusion. Its stock was suspended for about a month from Nov. 15, 2018.

Stock exchange authorities will determine the fate of Sillajen on Jan. 18, whose stock trade have been suspended since May 4, 2020 due to breach of trust and embezzlement charges.

[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?